A comparative study of Cyclofem® and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature

Journal of Family Planning and Reproductive Health Care

Volumn 33, Issue 4, 2007, Pages 271-276

  Simbar, Masoumeh ^a   Tehrani, Fahimeh Ramezani ^b   Hashemi, Zeinab ^c   Zham, Hananeh ^a   Fraser, Ian S ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cyclofem ; DMPA; Endometrial vasculature; Injectable contraceptive methods; Irregular bleeding

Indexed keywords

CD34 ANTIGEN; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENSTRUATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; STUDENT T TEST; VASCULARIZATION;

EID: 35348973985     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118907782101887     Document Type: Article

References (33)

1. Smith OP, Critchley HO. Progestogen-only contraception and endometrial break-through bleeding. Angiogenesis 2005; 8: 117-126.
2. Mishell DR. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41: 381-390.
3. Sangi-Haghpeykar H, Poindexter AN, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 1996; 88: 227-233.
4. Fraser IS. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. Contraception 1994; 49: 399-420.
5. d'Arcangues C. Once-a-month injectable contraceptives. World Health Forum 1993; 14: 439-440.
6. Hassan EO, el-Nahal N, el-Hussinie M. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Contraception 1999; 60: 87-92.
7. d'Arcangues C. Once-a-month estrogen/progestogen injectables. Entre Nous Cph Den 1991; 15.
8. Fraser IS, Hickey M, Song JY. Mechanisms of menstrual bleeding: dysfunctional uterine bleeding and breakthrough bleeding. Hum Reprod 1996; 11(Suppl. 2): 156-178.
9. Hourihan HM, Sheppard BL, Bonnar J. A morphometric study of the effects of oral norethisterone and levonorgestrel and endometrial blood vessels. Contraception 1986; 34: 603-612.
10. Johannisson E. Endometrial morphology during the normal cycle and under the influence of contraceptive steroids. In: d'Arcangues C, Fraser IS, Newton JR, Odlind V (eds), Contraception and Mechanisms of Endometrial Bleeding. Cambridge, UK: Cambridge University Press, 1990; 53-81.
11. Hickey M, Simbar M, Young L, Markham R, Russell P, Fraser IS. A longitudinal study of changes in endometrial microvascular density in Norplant implant users. Contraception 1999; 59: 123-129.
12. Rogers PAW, Au CL, Affandi B. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993; 8: 1396-1404.
13. Song JY, Markham R, Russell P, Wong T, Young L, Fraser IS. The effect of high dose, medium and long-term progestogen exposure on endometrial vessels. Hum Reprod 1995; 10: 797-800.
14. Hickey M, Dwarte D, Fraser IS. The endometrial vascular appearance in Norplant users: preliminary results from a hysteroscopic study. Hum Reprod 1996; 11(Suppl. 2): 35-44.
15. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986; 4: 253-260.
16. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3-25.
17. Shaw ST Jr, Macaulay LK, Hohman WR. Vessel density in endometrium of women with and without intrauterine contraceptive devices: a morphometric evaluation. Am J Obstet Gynecol 1979; 135: 202-206.
18. Shaw ST, Macaulay LK, Aznar R, Gonzalez-Angulo A, Roy S. Effects of a progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study. Am J Obstet Gynecol 1981; 141: 821-827.
19. Jondet M, Letellier B, Verdys MT. Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study. Contraception 2005; 71: 60-64.
20. Girling JE, Heryanto B, Patel N, Rogers PA. Effect of long-term progestin treatment on endometrial vasculature in normal cycling mice. Contraception 2004; 70: 343-350.
21. Simbar M, Manconi F, Markham R, Hickey M, Fraser IS. A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, Norplant. Micron 2004; 35: 589-595.
22. Hickey M, Simbar M, Markham R, Young L, Manconi F, Russell P, et al. Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod 1999; 14: 716-721.
23. McGavigan CJ, Dockery P, Metaxa-Mariatou V, Campbell D, Stewart CJ, Cameron IT, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod 2003; 18: 77-84.
24. Hickey M, Fraser IS. The structure of endometrial microvessels. Hum Reprod 2000; 15(Suppl. 3): 57-66.
25. Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 2000; 15(Suppl. 3): 135-143.
26. Vincent AJ, Zhang J, Ostor A, Rogers PA, Affandi B, Kovacs G, et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding. Hum Reprod 2002; 17: 1189-1198.
27. Galant C, Vekemans M, Lemoine P, Kokorine I, Twagirayezu P, Henriet P, et al. Temporal and spatial association of matrix metalloproteinases with focal endometrial breakdown and bleeding upon progestin-only contraception. J Clin Endocrinol Metab 2000; 85: 4822-4834.
28. Hickey M, Crewe J, Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA. Mechanism of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrin Metab 2006: 91: 3189-3198 [Epub 9 May 2006].
29. Lockwood CJ, Krikun G, Hausknecht VA, Papp C, Schatz F. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 1998; 139: 4607-4013.
30. Bahamondes L, Maradiegue E, Diaz J, Trelles J, Escanhoela C, Petta C, et al. Endometrial histology in long-term users of the once-a-month injectable contraceptive Cyclofem. Adv Contracept 1999; 15: 1-7.
31. Cuong DT, My Huong NT. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. Contraception 1996; 54: 169-179.
32. Davidson RA, Kalmus D, Cushman LF, Romero D, Heartwell S, Rulin M. Injectable contraceptive discontinuation and subsequent unintended pregnancy among low-income women. Am J Public Health 1997; 87: 1532-1534.
33. Trussell J, Vaughan B. Contraceptive failure, method related discontinuation and resumption of use: results from the 1995 national survey of family growth. Fam Plann Perspect 1999; 31: 64-72, 93.